| Name | Title | Contact Details |
|---|
Meet Twiage: An award-winning mobile communication technology that enables hospitals and EMS to accelerate life-saving emergency care by reducing the need of radio and phone communication. Twiage offers Hospitals & Emergency Departments: - Real-time prehospital clinical data for Stroke, STEMI, Trauma, and Sepsis, as well as all other EMS transports - HIPAA-compliant Videos, Photos, and EKGs - Patient Pre-Registration - GPS-tagged ETA for every incoming ambulance, optimizing ED flow and triage - Two-way communication capabilities for intra-hospital care coordination and inter-facility transfers. Twiage offers EMS: - Faster handoffs and ED turnaround times - No more reliance on radios! - HIPAA-compliant video, photos, and data capture sent directly to entire hospital teams - Simple, evidence-driven algorithms that help improve quality handoffs - Ability to create custom algorithms to match your clinical protocols Awards: Pulse @ MassChallenge, Platinum Award, 2017 MATTER Chicago, Observation Unit Challenge - Winner, 2017 American Heart/Stroke Association, Health Tech Competition - People`s Choice Award, 2016 American Medical Association, Healthier Nation Challenge - 1st Place Winner, 2016 Aspen Institute, Spotlight Health Finalist, 2016 Cornell Venture Challenge - 2nd Place Winner, 2016 Cleveland Clinic, New Ventures Healthcare Challenge - Winner, 2015 Massachusetts Medical Society, Information Technology Award, 2014 mHealth, Rockstar of the Year for most meaningful mobile health technology, 2014
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.
With our focus on improving patient outcomes with evidence-based healing solutions, we develop, market and distribute biotechnology products to physicians, hospitals, clinics and all post-acute care settings. We are constantly seeking long-term partnerships with a focus on products that produce efficacious outcomes at a lower overall cost. Our products are primarily sold in the North American surgical tissue repair and advanced wound care markets.
BeneFit Cosmetics LLC is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. BeneFit Cosmetics LLC is based in San Francisco, CA. You can find more information on BeneFit Cosmetics LLC at www.benefitcosmetics.com
Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by active participation in the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation.